Hypha Labs AI Stock Analysis
Want to see FUNI full AI Analyst Report?
Hypha Labs (FUNI) AI Stock Analysis
Hypha Labs
(Other OTC:FUNI)
The score is primarily held down by very weak financial performance (zero revenue, sizable losses, negative equity, and continued cash burn). Technical indicators also lean bearish (negative MACD, RSI in the mid-30s, and price below short-term moving averages). Valuation provides little support given the negative P/E and lack of dividend yield.
Hypha Labs (FUNI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $327.79K
- Dividend Yield
- ―
- Average Volume (3M)
- 391.26K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.33
- Revenue Growth
- ―
- EPS Growth
- 47.23%
- Country
- US
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Hypha Labs Business Overview & Revenue Model
Company Description
Hypha Labs, Inc. focuses on the investigation, development, and market release of bioreactor systems across the United States. Their key offering is the Hypha Micropearl bioreactor, a specialized household device engineered to rapidly cultivate benef...
How the Company Makes Money
null
Hypha Labs Financial Statement Overview
Summary
Financial performance is extremely weak: TTM shows zero revenue, large operating and net losses, negative equity, and ongoing negative operating and free cash flow. Reduced cash burn versus the prior year is a modest positive, but overall results indicate high funding and execution risk.
Income Statement
12Very NegativeBalance Sheet
10Very NegativeCash Flow
18Very Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 2.70M | 2.50M |
| Gross Profit | -23.96K | 0 | 0 | 0 | 1.07M | 715.16K |
| EBITDA | -1.47M | -2.95M | -1.37M | -58.24K | -1.73M | -249.00K |
| Net Income | -1.91M | -3.10M | -785.00K | 246.77K | -2.06M | -687.00K |
Balance Sheet | ||||||
| Total Assets | 68.33K | 409.22K | 493.81K | 1.41M | 1.34M | 1.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5,110 | 38.12K | 91.17K | 271.01K | 56.17K | 295.93K |
| Total Debt | 1.79M | 1.65M | 1.14M | 2.29M | 2.35M | 2.79M |
| Total Liabilities | 3.16M | 2.51M | 1.42M | 3.28M | 4.08M | 2.94M |
| Stockholders Equity | -3.09M | -2.10M | -926.69K | -1.87M | -2.41M | -1.05M |
Cash Flow | ||||||
| Free Cash Flow | -599.29K | -412.94K | -1.42M | 112.52K | -202.51K | -192.17K |
| Operating Cash Flow | -568.05K | -379.98K | -1.39M | 112.53K | -184.79K | -135.97K |
| Investing Cash Flow | -31.24K | -32.97K | 2.15M | 263.33K | -660.37K | -286.21K |
| Financing Cash Flow | 457.21K | 359.89K | -1.28M | -161.02K | 605.39K | 635.36K |
Hypha Labs Risk Analysis
Hypha Labs disclosed 32 risk factors in its most recent earnings report. Hypha Labs reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHypha Labs Peers Comparison
Overall Rating
PRPO60Neutral
INBS54Neutral
BIAF42Neutral
FUNI41Neutral
ISPC40Underperform
TRIB38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | $39.68M | -36.61 | -7.84% | ― | 21.76% | 22.97% | |
| 54Neutral | $5.84M | -0.26 | -146.09% | ― | 36.55% | 60.09% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | $4.00M | -0.04 | -331.02% | ― | -18.47% | 87.82% | |
| 41Neutral | $475.30K | -0.16 | 73.84% | ― | ― | 47.23% | |
| 40Underperform | $1.66M | -0.01 | -524.37% | ― | -92.11% | 86.78% | |
| 38Underperform | $3.93M | -0.13 | 48.72% | ― | -13.28% | 39.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FUNI | Hypha Labs, Inc. | 0.01 | -0.01 | -56.00% | |
| TRIB | Trinity Biotech | 6.10 | -18.47 | -75.17% | |
| PRPO | Precipio | 22.13 | 1.10 | 5.23% | |
| INBS | Intelligent Bio Solutions Inc. | 1.76 | -5.16 | -74.57% | |
| ISPC | Ispecimen Inc | 0.66 | -22.55 | -97.17% | |
| BIAF | bioAffinity Technologies, Inc. | 2.20 | -21.50 | -90.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 18, 2026
